These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Contemporary thoughts on the treatment of irritable bowel syndrome. Giaquinta D Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060 [No Abstract] [Full Text] [Related]
3. FDA advisory panels recommend Lotronex be put back on market. Charatan F BMJ; 2002 May; 324(7345):1053. PubMed ID: 11993482 [No Abstract] [Full Text] [Related]
4. Alosetron to return to market. Young D Am J Health Syst Pharm; 2002 Jul; 59(14):1323-4. PubMed ID: 12132555 [No Abstract] [Full Text] [Related]
5. FDA draws patients into alosetron risk management. Miller JL Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021 [No Abstract] [Full Text] [Related]
6. Alosetron: a case study in regulatory capture, or a victory for patients' rights? Moynihan R BMJ; 2002 Sep; 325(7364):592-5. PubMed ID: 12228140 [No Abstract] [Full Text] [Related]
7. Lotronex and the FDA: a fatal erosion of integrity. Horton R Lancet; 2001 May; 357(9268):1544-5. PubMed ID: 11377636 [No Abstract] [Full Text] [Related]
8. So what happened to alosetron? Hyams JS J Pediatr Gastroenterol Nutr; 2001 May; 32(5):513-4. PubMed ID: 11455947 [No Abstract] [Full Text] [Related]
9. FDA advisers warn of more deaths if drug is relaunched. Moynihan R BMJ; 2002 Sep; 325(7364):561. PubMed ID: 12228121 [No Abstract] [Full Text] [Related]
10. A pill turned bitter. How a quest for a blockbuster drug went fatally wrong. Shapiro JP US News World Rep; 2000 Dec; 129(23):54-6. PubMed ID: 11126059 [No Abstract] [Full Text] [Related]
11. Irritable bowel syndrome. A poorly understood disorder. Lewis C FDA Consum; 2001; 35(4):30-6. PubMed ID: 11692885 [No Abstract] [Full Text] [Related]
12. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky. Horwitz BJ Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480 [No Abstract] [Full Text] [Related]
13. Alosetron approved for treatment of irritable bowel syndrome. Miller JL Am J Health Syst Pharm; 2000 Mar; 57(6):519. PubMed ID: 10754758 [No Abstract] [Full Text] [Related]
14. Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown. Palmer RH BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12518769 [No Abstract] [Full Text] [Related]
15. FDA approves restricted marketing of Lotronex. FDA Consum; 2002; 36(4):4. PubMed ID: 12184306 [No Abstract] [Full Text] [Related]
16. Lotronex withdrawn from market. Harv Womens Health Watch; 2001 Feb; 8(6):6. PubMed ID: 11175468 [No Abstract] [Full Text] [Related]
17. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome. McGahan L Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219 [No Abstract] [Full Text] [Related]
18. Alosetron use drops dramatically with risk management. Traynor K Am J Health Syst Pharm; 2004 Jun; 61(12):1210-2. PubMed ID: 15259746 [No Abstract] [Full Text] [Related]
19. Alosetron for irritable bowel syndrome. Lièvre M BMJ; 2002 Sep; 325(7364):555-6. PubMed ID: 12228116 [No Abstract] [Full Text] [Related]
20. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D; Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]